Skip to main content

Table 1 Characteristics of cohort studies of metabolic syndrome and prostate cancer risk

From: The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence

Author yr (ref. no.) Country Population Mean age, yr Mean FU time, yr Time period Cohort size Definition of MetS No. of cases RRs 95% CI Controlled variables
Laukkanen 2004 [11] Finland Kuopio communities 52.6 15 1984-2001 1,880 WHO 56 RR 1.90 1.1-3.5 Age
Tande 2006 [12] United States ARIC* (49% white, 51% African American) 45-64 12.1 1987-2000 6,429 NCEP-ATP-III 385 RR 0.77 0.60-0.98 Age, race
Russo 2008 [13] Italy A pharmacologically based diagnosis 40 2.7 1999-2005 NA A pharmacologically based diagnosis 94 RR 0.93 0.75-1.14 Age
Martin 2009 [14] Norway HUNT2 48 ± 16.4 9.3 1996-2005 29,364 NCEP-ATP-III 687 RR 0.91 0.77-1.09 Age+
Inoue 2009 [15] Japan Japan PHC population 40-69 10.2 1993-2004 9,548 IDF 119 HR 0.76 0.47-1.22 Age+
Grundmark 2010 [16] Sweden ULSAM 50 30.3 1970-2003 2,183 NCEP-ATP-III 226 RR 1.29 0.89-1.88 Age
2,287 IDF 234 RR 1.18 0.81-1.71
Wallner 2010 [17] United States Olmsted County 40-79 15 1990-NA 2,445 WHO 206 HR 0.65 0.37-1.10 Age
Osaki 2011 [18] Japan The population-based cancer registry 60.5 ± 10.8 9.3 1992-2007 8,239 NCEP-ATP-III 152 HR 1.37 0.91-2.06 Age
8,239 IDF 152 HR 1.18 0.74-1.90
Häggström 2012 [19] Norway Me-Can 44 12 NA 289,866 Upper quartile levels ATP-III criteria 6,922 RR 0.96 0.92-1.00 Age+
Sweden
Austria
  1. MetS = metabolic syndrome; PCa = prostate cancer; RRs = Relative risks; CI = confidence interval; Age + =At least age; WHO = World Health Organization; NCEP-ATP-III = National Cholesterol Education Program Adult Treatment Panel III; IDF = International Diabetes Federation; HUNT 2 = Nord-Trondelang Health Study; ARIC = Atherosclerosis Risk in Communities; OR = odds ratio; *We use White-American data.